Na05

General Information


DRACP ID  DRACP01780

Peptide Name   Na05

Sequence  RRNDLRSXFLTLRDXVP

Sequence Length  17

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetics

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients Glioblastoma Blastoma EC50≈10 μM CYTELL assay 72-96 h Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na07) links both Xs radicals in each sequence

Chiral  L



Physicochemical Information


Formula  C80H132N28O21

Absent amino acids  ACEGHIKMQWY

Common amino acids  R

Mass  232766

Pl  12.02

Basic residues  4

Acidic residues  2

Hydrophobic residues  5

Net charge  2

Boman Index  -6795

Hydrophobicity  -77.65

Aliphatic Index  85.88

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US2020/0157150A1

Patent Title  Anticancer Peptides

Other Iinformation  Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status: Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017

Other Published ID  AU2018311129A1  CA3071601A1  CN111436200A  EP3661947A1  JP2020529429A  KR20200032730A  WO2019025432A1 




DRACP is developed by Dr.Zheng's team.